Development and characterization of functionalized niosomes for brain targeting of dynorphin-B.
暂无分享,去创建一个
S Furlanetto | S Orlandini | P Mura | S. Furlanetto | S. Orlandini | C. Ghelardini | P. Mura | N Mennini | M. Bragagni | M Bragagni | C Ghelardini | N. Mennini | C. Ghelardini | Paola Mura
[1] Wen-Yih Chen,et al. Microcalorimetric and shear studies on the effects of cholesterol on the physical stability of lipid vesicles , 2000 .
[2] Uchiyama,et al. The size of liposomes: a factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs. , 1999, Advanced drug delivery reviews.
[3] S Furlanetto,et al. Quality by design approach for developing chitosan-Ca-alginate microspheres for colon delivery of celecoxib-hydroxypropyl-β-cyclodextrin-PVP complex. , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[4] N. Hayward,et al. Neuroprotective actions of GR89696, a highly potent and selective κ‐opioid receptor agonist , 1991 .
[5] Dora Brites,et al. Looking at the blood–brain barrier: Molecular anatomy and possible investigation approaches , 2010, Brain Research Reviews.
[6] R. Spealman,et al. Opioid modulation of the discriminative stimulus effects of cocaine: comparison of µ, kappa and delta agonists in squirrel monkeys discriminating low doses of cocaine. , 1994, Behavioural pharmacology.
[7] S. Furlanetto,et al. Study of formulation variables influencing the drug release rate from matrix tablets by experimental design. , 2006, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[8] C. Ghelardini,et al. Development and characterization of niosomal formulations of doxorubicin aimed at brain targeting. , 2012, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
[9] R. Duncan,et al. Niosomes containing N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin (PK1) : effect of method of preparation and choice of surfactant on niosome characteristics and a preliminary study of body distribution , 1997 .
[10] Roger Phan-Tan-Luu,et al. Pharmaceutical Experimental Design , 1998 .
[11] Mayur M. Patel,et al. Getting into the Brain , 2009, CNS Drugs.
[12] H. Davson,et al. Kinetic Analysis of Leucine‐Enkephalin Cellular Uptake at the Luminal Side of the Blood‐Brain Barrier of an In Situ Perfused Guinea‐Pig Brain , 1989, Journal of neurochemistry.
[13] Sandra Furlanetto,et al. Didanosine extended-release matrix tablets: optimization of formulation variables using statistical experimental design. , 2002, International journal of pharmaceutics.
[14] D. Craig,et al. The effect of processing variables on the physical characteristics of non-ionic surfactant vesicles (niosomes) formed from a hexadecyl diglycerol ether. , 2000, International journal of pharmaceutics.
[15] D. Singodia,et al. Excipient Selection In Parenteral Formulation Development , 2013 .
[16] S. Furlanetto,et al. Response surface methodology in the optimization of chitosan-Ca pectinate bead formulations. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[17] James K Drennen,et al. Performance-based quality specifications: the relationship between process critical control parameters, critical quality attributes, and clinical performance. , 2011, Journal of pharmaceutical sciences.
[18] F. Rinaldi,et al. Niosomes from 80s to present: the state of the art. , 2014, Advances in colloid and interface science.
[19] L. Tetley,et al. Niosomes and Polymeric Chitosan Based Vesicles Bearing Transferrin and Glucose Ligands for Drug Targeting , 2000, Pharmaceutical Research.
[20] G. Pasternak,et al. Improved Brain Uptake and Pharmacological Activity of Dalargin Using a Peptide-Vector-Mediated Strategy , 2003, Journal of Pharmacology and Experimental Therapeutics.
[21] Jing Qin,et al. Surface modification of RGD-liposomes for selective drug delivery to monocytes/neutrophils in brain. , 2007, Chemical & pharmaceutical bulletin.
[22] S Furlanetto,et al. Optimization of glibenclamide tablet composition through the combined use of differential scanning calorimetry and D-optimal mixture experimental design. , 2005, Journal of pharmaceutical and biomedical analysis.
[23] D. A. Kharkevich,et al. Delivery of Loperamide Across the Blood-Brain Barrier with Polysorbate 80-Coated Polybutylcyanoacrylate Nanoparticles , 1997, Pharmaceutical Research.
[24] V. Sankar,et al. NIOSOME DRUG DELIVERY SYSTEM: ADVANCES AND MEDICAL APPLICATIONS - AN OVERVIEW , 2009 .
[25] R. Spealman,et al. Opioid modulation of the discriminative stimulus effects of cocaine: comparison of μ, k and δ agonists in squirrel monkeys discriminating low doses of cocaine , 1994 .
[26] A. Schätzlein,et al. Glucose-targeted niosomes deliver vasoactive intestinal peptide (VIP) to the brain. , 2004, International journal of pharmaceutics.
[27] D. V. Kohli,et al. Transferrin coupled liposomes as drug delivery carriers for brain targeting of 5-florouracil , 2005, Journal of drug targeting.
[28] G. Golomb,et al. Delivery of serotonin to the brain by monocytes following phagocytosis of liposomes. , 2008, Journal of controlled release : official journal of the Controlled Release Society.
[29] A. Pardakhty,et al. Nano-niosomes in drug, vaccine and gene delivery: a rapid overview , 2013 .
[30] A. Schätzlein,et al. Anticancer Drug Delivery with Transferrin Targeted Polymeric Chitosan Vesicles , 2004, Pharmaceutical Research.
[31] J. Álvarez-Fuentes,et al. Development of sustained release matrix tablets of didanosine containing methacrylic and ethylcellulose polymers. , 2002, International journal of pharmaceutics.
[32] D. Begley,et al. Direct Evidence That Polysorbate-80-Coated Poly(Butylcyanoacrylate) Nanoparticles Deliver Drugs to the CNS via Specific Mechanisms Requiring Prior Binding of Drug to the Nanoparticles , 2003, Pharmaceutical Research.
[33] L. Brady,et al. Analgesic effects of intraventricular morphine and enkephalins in nondependent and morphine-dependent rats. , 1982, The Journal of pharmacology and experimental therapeutics.
[34] N. Mello,et al. Kappa opioid agonists as targets for pharmacotherapies in cocaine abuse. , 2000, Pharmaceutica acta Helvetiae.
[35] W. Pardridge. The blood-brain barrier: Bottleneck in brain drug development , 2005, NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics.
[36] M. Adler,et al. Antinociceptive action of intracerebroventricularly administered dynorphin and other opioid peptides in the rat. , 1988, The Journal of pharmacology and experimental therapeutics.
[37] F. Szoka,et al. Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating , 2005, Brain Research.
[38] W. Pardridge. Molecular Regulation of Blood-Brain Barrier GLUT1 Glucose Transporter , 1995 .
[39] S. Welch,et al. Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP55,940 in the spinal cord. , 1997, The Journal of pharmacology and experimental therapeutics.
[40] I. Uchegbu,et al. Vesicles prepared from synthetic amphiphiles — polymeric vesicles and niosomes , 2006 .
[41] W. Pardridge,et al. Blood-brain barrier delivery. , 2007, Drug discovery today.
[42] R. Koehler,et al. Neuroprotective Effect of Selective Kappa Opioid Receptor Agonist is Gender Specific and Linked to Reduced Neuronal Nitric Oxide , 2006, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[43] R. Imberti,et al. Drug delivery to the central nervous system , 2010 .
[44] Ijeoma F. Uchegbu,et al. Non-ionic surfactant based vesicles (niosomes) in drug delivery , 1998 .
[45] Hideyoshi Harashima,et al. Enhanced Hepatic Uptake of Liposomes Through Complement Activation Depending on the Size of Liposomes , 1994, Pharmaceutical Research.
[46] Jean-Pierre Benoit,et al. Active targeting of brain tumors using nanocarriers. , 2007, Biomaterials.
[47] B. Sabel,et al. Efficacy of Oral Dalargin-loaded Nanoparticle Delivery across the Blood–Brain Barrier , 1998, Peptides.
[48] P. Couvreur,et al. Colloidal carriers and blood-brain barrier (BBB) translocation: a way to deliver drugs to the brain? , 2005, International journal of pharmaceutics.
[49] D. Aggarwal,et al. Vesicular systems in ocular drug delivery: an overview. , 2004, International journal of pharmaceutics.